Abstract
A NOVEL ASSOCIATION BETWEEN ANTI-CARBAMYLATED ANTIBODIES AND INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Full text
Background: Interstitial lung disease (ILD) is associated with a significant increase in morbidity and mortality in patients with rheumatoid arthritis (RA). Therefore, an early diagnosis is fundamental. Anti-carbamylated proteins (Anti-CarP) have been described in different chronic respiratory diseases without a previous history of RA.
Objectives: The aim of this study was to analyse the association between Anti-CarP and ILD in RA patients.
Methods: We performed a cross-sectional study, including RA patients fulfilling the 2010 ACR/EULAR criteria. The main population comprised 2 groups: 1) RA patients diagnosed with ILD (RA-ILD group) and 2) RA patients without ILD (non-ILD RA group). ILD was diagnosed by high-resolution tomography and confirmed by a multidisciplinary committee. Three IgG Anti-CarP autoantibodies against fetal calf serum (Anti-FCS), fibrinogen (Anti-Fib), and fibrine/filagrine homocitrullinated peptide (Anti-CFFHP) and one IgA against FCS (Anti-FCS-IgA) were determined by home-made ELISA. Associations between Anti-CarPs and ILD were explored using multivariable logistic regression adjusted by a set of variables known to be related to the development of ILD: smoking, sex, age, RA disease duration, RF and ACPA. An independent replication sample was obtained to validate our findings from another hospital.
Results: The main population included 179 patients: 37 were included in the RA-ILD group, and 142 in the non-ILD RA group. Most patients were female (79%), with a mean age of 59.7±13 years with a mean disease duration of 6.6±5 years. Baseline features are shown in
table 1
. The replication sample was composed of 25 patients in the RA-ILD group and 50 patients in the non-ILD RA group. We found that Anti-CarPs specificities were more frequent in RA-ILD patients (Anti-FCS 70% vs. 43%; Anti-Fib 73% vs. 51%; Anti-CFFHP 38% vs. 19%; Anti-CarP-IgA 51% vs. 20%, p<0.05 for all comparisons). Serum mean titers of Anti-CarPs were higher in RA-ILD patients with significant statistical differences for all of them, except Anti-Fib. The multivariate analysis showed that Anti-CarPs specificities were independently associated with ILD (Anti-FCS (OR: 3.42; CI95%: 1.13-10.40), Anti-Fib (OR: 2.85; CI95%: 0.83-9.70), Anti-CFFHP (OR: 3.11; CI95%: 1.06-9.14) and Anti-FCS-IgA (OR: 4.30; CI95%: 1.41-13.04). In the replication sample our findings were validated only for Anti-FCS (OR: 10.42; CI95%: 1.68-64.46).
TABLE 1.
Main population demographic, clinical, therapeutic, and autoantibody status features.
RA-ILD
n:37
Non-ILD RA
n:142
p value
Female (%)
25 (68)
116 (82)
NS
Age mean (±SD)
67.3 (10.1)
57.7 (12.9)
<0.005
Mean disease duration (±SD)
11.6 (7.1)
5.3 (13.3)
<0.005
Ever smokers (%)
21 (57)
62 (44)
NS
Smoking cumulative dose (±SD)
30.7 (11.1)
21.8 (12)
<0.005
Caucasian (%)
31 (84)
120 (85)
NS
Treatment
Glucocorticoids (%)
25 (68)
81 (57)
NS
csDMARDs (%)
33 (89)
132 (86)
NS
MTX (%)
20 (54)
95 (67)
NS
bDMARDs (%)
11 (30)
36 (25)
NS
Mean DAS28 (±SD)
3.71 (1.35)
2.74 (1.05)
<0.005
Erosive disease (%)
26 (70)
63 (44)
<0.005
Mean HAQ-DI (CI-95%)
0.69 (0.53-0.85)
0.31 (0.24-0.38)
<0.005
ACPA positive (%)
29 (78)
99 (70)
NS
Median titer ACPA (IQR) CU
674 (2,215)
143 (1,132)
NS
RF positive (%)
28 (76)
83 (59)
NS
Median titer RF (IQR) IU
105 (298)
34 (110)
NS
Conclusion: A strong association between RA-ILD and Anti-CarP was found independently of cofounders, including RF and ACPA. Our findings suggest a possible link between Anti-CarP and the development of ILD.
Disclosure of Interests: Raul Castellanos-Moreira Speakers bureau: Lilly, MSD, Sanofi, UCB, Sebastian Rodriguez-Garcia: None declared, Katherine Cajiao: None declared, Gabriela Jimenez: None declared, Maria Jose Gomara: None declared, Virginia Ruiz Speakers bureau: Lilly, Pfizer, Ivette Casafont-Solé: None declared, Julio Ramirez: None declared, José Gomez Puerta Speakers bureau: Abbvie, Eli Lilly, BMS, Roche and Pfizer, Susana Holgado Pérez: None declared, Juan de Dios Cañete: None declared, Isabel Haro: None declared, Raimón Sanmartí Speakers bureau: Abbvie, Eli Lilly, BMS, Roche and Pfizer
Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 940Session: Rheumatoid arthritis - prognosis, predictors and outcome
(Poster Presentations)
3 organizations
Organization
IQAC-CSIC, Barcelona, Spain